At the news
? BULLISHIMPACT 7/10 6-K filed Aug 31, 2026 at 08:00 ET
Alpha Tau completed enrollment in its IMPACT pilot study of Alpha DaRT for pancreatic cancer, enrolling 48 patients (4x the original 12) after three expansions driven by strong demand. This de-risks the pancreatic program and supports the design of a planned pivotal study, with initial data expected in early 2027. The filing is a positive clinical milestone for a pre-commercialization company with a $1.4B market cap and strong analyst consensus.
- IMPACT study enrolled 48 patients, expanded three times from original 12-patient design
- Study conducted under U.S. IDE across 10 centers in US, Canada, and Israel
- Alpha DaRT delivered as one-time add-on to first-line chemotherapy (mFOLFIRINOX or gemcitabine + nab-paclitaxel)
- Initial data targeted for early 2027 to inform pivotal study design
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access